Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Dec 16, 2023 2:34pm
532 Views
Post# 35788352

Many unknowns, one thing we know for sure

Many unknowns, one thing we know for sure

In the past week, or so there have surfaced many corporate changes/ modifications.
Andew D is gone. Perhaps fired, quit, we don't know.
A new scientific advisory committee member has been added.
Now a posting for a " medical writer" 
Options available, no solid conclusions yet if Matt utilized or not. That reporting is due next few days.
These are all significant corporate changes. 
I agree hiring a medical writer indicates plans to ramp up for something.

Imho, weekend comentsry
 
Those who have been around longer than a few years, know full well.
1. Onc has mutiple sucsesses with Roche. Aka Goblet trials. 3 out if 4 arms, yeilded well above standard of care resukts.
2. They have answered every possible question, pre- phase 3 for MBc & Pancreatice cancer.
3. The PanCan approval was pulled, not of anything to do with Onc, but PanCan delays of federal funding. Yet they still committed to the $5million grant. To add an additional arm, for Pancreatic cancer.
4. There are more than 3 lower attention opportunities, not dead, but not being discussed.
Car-t , being one.
conclusion, on the science side they have carried the ball as far as it can go.
Now it's time to make a deal & move forward.

Again anyone around for a few years or more can agree.
Management knows that The B.O.D. Knows that.
All the analysts know that.

Observationalky ?

Very strange management changes. Anyone can spin the information anyway you want.
My bottom line?
They are in process of changing for a better future. You. Don't add positions if the company sees trouble ahead.
The phase 3 trial(s) will start.How & with who? We will see soon.

On the $$ side of Things? Corporate structure. Share dillution etc etc.?
im still of the opinion a buyout is the best option at this time.
Regardless of any speculations, we will know a lot more before year end.
At this stage, nothing would surprise me.
Best of health & wellbeing all the Onc chat folks. Let's hope 2024 is better than 2023.

 


 

<< Previous
Bullboard Posts
Next >>